New drug to prevent migraine may start working in days

June 08, 2016

MINNEAPOLIS - A new drug to prevent migraine was associated with fewer headache hours for people with chronic migraine within three to seven days after the first injection, according to a study published in the June 8, 2016, online issue of Neurology®, the medical journal of the American Academy of Neurology. Chronic migraine is defined as headaches occurring at least 15 days per month. Study participants had migraine attacks for an average of 20 years prior to treatment.

"Chronic migraine affects about 1 percent of all adults, yet less than 5 percent of those people receive a correct diagnosis and appropriate treatment," said study author Marcelo Bigal, MD, PhD, of Teva Pharmaceuticals in Frazer, Penn., which developed the new drug, called TEV-48125. "Most people who receive preventive medication for chronic migraine stop using them, and one reason for that is the drugs can take a long time to become effective. If these results can be confirmed with larger studies, this could be exciting for people with migraine."

TEV-48125 is an antibody that blocks the calcitonin gene-related peptide that plays a role in migraine pain. The study involved 261 people who had migraine for an average of 18 years. They had an average of 162 hours of headaches a month and an average of 22 days with headache per month.

Of the participants, 87 people received a monthly shot for three months with a low dose of the drug, 85 people received a high dose and 89 people received a placebo shot. The participants used an electronic diary to record their headaches. The phase 2b study was conducted to look for the results after three months, and the positive results were published. For this study, the researchers reanalyzed the results to look at the results on headache hours and days in the first days and weeks of the study.

After one week, the average number of headache hours went down by 2.9 hours for people taking the placebo, 9.1 hours for people taking the low dose of TEV-48125 and 11.4 hours for those taking the high dose. The higher dose first showed a difference from the placebo after three days, with 3.1 fewer headache hours, compared to an additional 0.4 hours for the placebo. The lower dose showed a difference from the placebo after seven days, with 7.3 fewer headache hours, compared to 1.6 fewer hours for the placebo.

For the number of days with moderate or severe headaches, both doses showed a difference from placebo after two weeks of treatment, with headaches reduced by 0.8 days for placebo, 1.3 days for the low dose and 1.5 days for the high dose.

Bigal noted that study limitations include that the analyses for the early results were not defined before the study was conducted and that study participants were not asked whether the results in the first days of the study were large enough to be meaningful for them.
-end-
The study was supported by Teva Pharmaceuticals.

To learn more about headache, please visit http://www.aan.com/patients.

The American Academy of Neurology, the world's largest association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube.

American Academy of Neurology

Related Migraine Articles from Brightsurf:

Disparities in migraine by sexual orientation
Survey data were used to examine the association between sexual orientation (exclusively heterosexual, mostly heterosexual, lesbian, gay or bisexual) and migraine.

Can you paint your migraine?
'Can you draw me a picture of your headache?' may sound like an unusual question - but drawings of headache pain provide plastic surgeons with valuable information on which patients are more or less likely to benefit from surgery to alleviate migraine headaches.

Acupuncture can reduce migraine headaches
Acupuncture can reduce migraine headaches compared to both sham (placebo) acupuncture and usual care, finds a new trial from China published by The BMJ today.

Migraine rats, medical facts
Migraine mechanisms are still far from being fully understood. Escalating data from animal models are 'fact-checking' the neurophysiological and behavioral correlates of the migraine experience in humans, and how they may be affected by current anti-migraine drugs or might translate into new therapies.

Connecting the dots in the migraine brain
This dMRI study pointed to the structural strengthening of connections involving subcortical regions associated with pain processing and weakening in connections involving cortical regions associated with hyperexcitability may coexist in migraine.

Predictors of chronic migraine
A review and meta-analysis found predictors of chronic migraine. Depression, high frequency attacks, medication overuse and allodynia increased the chances for new onset chronic migraine, while annual income -- US$ 50,000 showed a protective effect.

On nitroglycerin, cardiovascular homeostasis and...bam, migraine!
Researchers in Leiden, The Netherlands, found an exaggerated cardiovascular response to nitroglycerin infusion in migraine patients, suggesting an elevated systemic sensitivity to this compound in this population.

All roads lead to migraine
Dr. Samaira Younis, from the Danish Headache Center in Copenhagen, Denmark, shares her research results, which suggests there are no differences between migraine attacks clinical characteristics following administration of 2 different compounds in patients, CGRP and sildenafil, meaning they share common cellular signaling pathways.

Running away from exercise: The curious case of migraine
In spite of the widespread recommendation for regular physical activity as a strategy to manage migraine, for some patients, exercise can instead trigger migraine attacks.

Migraine prevention in children and adolescents
Two medicines already used to prevent migraine in adults also showed efficacy in adolescents with migraine.

Read More: Migraine News and Migraine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.